Use of dipeptidyl peptidase IV inhibitors
AssigneeProbiodrug AG
InventorsHans-Ulrich Demuth, Torsten Hoffmann, Konrad Glund, Ulrich Heiser, Stephan von Hoersten
Life of this patent
Estimating the term…
Abstract
The present invention provides a new use of DP IV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DP IV or DP IV-like enzymes, such as immune, autoimmune or central nervous system disorder selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.
Claims15
A method for reducing an immune, autoimmune or central nervous system related disorders selected from the group consisting of strokes, tumors, ischemia, parkinson's disease, multiple sclerosis and migraines, comprising the step of administering a therapeutically effective amount of at least one inhibitor of dipeptidyl peptidase IV (DP IV) or DP IV-like enzyme activity.
A pharmaceutical composition comprising:
- an inhibitor of DP IV or DP IV-like enzyme activity or a pharmaceutically acceptable acid addition salt thereof for the manufacture of a medicament for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for the prevention or treatment of diseases or conditions related to dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzymes.
Dependencies are inferred from the claim text.